Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 10/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23696625 | 0.91 | CYP2D6 (0.45) | CYP2D6ALDH1A1CYP3A4MAPK1CYP2C9 | |
| SCHEMBL23806767 | 0.91 | CYP2D6 (0.44) | CYP2D6ALDH1A1CYP3A4MAPK1CYP2C9 | |
| SCHEMBL26405029 | 0.89 | CYP2D6 (0.48) | CYP2D6ALDH1A1CYP3A4MAPK1CYP2C9 | |
| SCHEMBL23560014 | 0.87 | CYP2D6 (0.61) | CYP2D6ALDH1A1CYP3A4MAPK1CYP2C9 | |
| SCHEMBL24673717 | 0.84 | CYP2D6 (0.47) | CYP2D6ALDH1A1CYP3A4MAPK1CYP2C9 | |
| SCHEMBL25923662 | 0.83 | CYP2D6 (0.47) | CYP2D6ALDH1A1CYP3A4MAPK1CYP2C9 | |
| SCHEMBL27107664 | 0.82 | CYP2D6 (0.56) | CYP2D6ALDH1A1CYP3A4MAPK1CYP2C9 | |
| SCHEMBL25887973 | 0.82 | CYP2D6 (0.41) | CYP2D6ALDH1A1CYP3A4MAPK1CYP2C9 | |
| SCHEMBL25479692 | 0.82 | CYP2D6 (0.48) | CYP2D6ALDH1A1CYP3A4MAPK1CYP2C9 | |
| SCHEMBL26405428 | 0.82 | L3MBTL1 (0.48) | CYP2D6ALDH1A1CYP3A4ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CYP2D6 3599/4885ALDH1A1 2776/4885CYP3A4 2542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.